相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
Laura M. McLane et al.
Annual Review of Immunology (2019)
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Benedetto Sacchetti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma
Zhitao Ying et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CD19 CAR-T cell therapy for relapsed / refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
Li-Na Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Mitochondria! Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Alvaro Teijeira et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Programming CAR-T cells to kill cancer
Louai Labanieh et al.
NATURE BIOMEDICAL ENGINEERING (2018)
High expression of TROP2 is correlated with poor prognosis of oral squamous cell carcinoma
Genxiong Tang et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Targeting Costimulatory Pathways in Systemic Sclerosis
Goncalo Boleto et al.
FRONTIERS IN IMMUNOLOGY (2018)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
Yinmeng Yang et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer
Timothy N. J. Bullock
CURRENT OPINION IN IMMUNOLOGY (2017)
Sacituzumab Govitecan, a Novel Antibody-Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma
Bishoy Faltas et al.
CLINICAL GENITOURINARY CANCER (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Engineered T cells: the promise and challenges of cancer immunotherapy
Andrew D. Fesnak et al.
NATURE REVIEWS CANCER (2016)
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Alexander N. Starodub et al.
CLINICAL CANCER RESEARCH (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Adoptive cellular therapy: A race to the finish line
Carl H. June et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M. Goldenberg et al.
ONCOTARGET (2015)
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Venky Ramakrishna et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Sonia Guedan et al.
BLOOD (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Trop-2 Promotes Prostate Cancer Metastasis By Modulating β1 Integrin Functions
Marco Trerotola et al.
CANCER RESEARCH (2013)
Gene-engineered T cells for cancer therapy
Michael H. Kershaw et al.
NATURE REVIEWS CANCER (2013)
CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo
De-Gang Song et al.
BLOOD (2012)
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells
Andreas A. Hombach et al.
ONCOIMMUNOLOGY (2012)
TROP2 Expressed in the Trunk of the Ureteric Duct Regulates Branching Morphogenesis during Kidney Development
Yuko Tsukahara et al.
PLOS ONE (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients
Eliana Bignotti et al.
EUROPEAN JOURNAL OF CANCER (2010)
The Pim Kinase Pathway Contributes to Survival Signaling in Primed CD8+ T Cells upon CD27 Costimulation
Victor Peperzak et al.
JOURNAL OF IMMUNOLOGY (2010)
Control of Established Melanoma by CD27 Stimulation Is Associated With Enhanced Effector Function and Persistence, and Reduced PD-1 Expression of Tumor Infiltrating CD8+ T Cells
Drew J. Roberts et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Trop2: A possible therapeutic target for late stage epithelial carcinomas
Rafael Cubas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2009)
Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver
Mayuko Okabe et al.
DEVELOPMENT (2009)
The role of TNF superfamily members in T-cell function and diseases
Michael Croft
NATURE REVIEWS IMMUNOLOGY (2009)
Late signals from CD27 prevent Fas-dependent apoptosis of primary CD8+ T cells
Douglas V. Dolfi et al.
JOURNAL OF IMMUNOLOGY (2008)
Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
Jianbo Wang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
CD27-CD70 interactions sensitise naive CD4(+) T cells for IL-12-induced T(h)1 cell development
Michiel F. van Osterk et al.
INTERNATIONAL IMMUNOLOGY (2007)
The many faces of IL-7: From lymphopoiesis to peripheral T cell maintenance
TJ Fry et al.
JOURNAL OF IMMUNOLOGY (2005)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
CD28-mediated co-stimulation: A quantitative support for TCR signalling
O Acuto et al.
NATURE REVIEWS IMMUNOLOGY (2003)
CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool
J Hendricks et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
分享论文
